$PJET watch this one, entire OS recently bought up
Post# of 72707
F-6Priority Aviation, Inc.Notes To Financial Statements(Unaudited)NOTE 1 - NATURE OF OPERATIONSPriority Aviation, Inc. (the “Company”) was organized under the laws of Nevada on March 25, 1999 as Thoroughbred Interests, Inc. OnMay 18, 2004, the Company changed its name to Phoenix Interests, Inc.; on July 14, 2009 the Company changed its name to NuMobile,Inc.; and on December 27, 2013, the Company changed its name to Priority Aviation, Inc. In 2017, the Company elected to exit its business and divested its subsidiaries in exchange for the acquirer’s assumption of the netliabilities. The Company recorded a net $17 million gain from this divestiture. The Company also acquired the business assets ofTelluride Health Company, (THC), in exchange for a $500,000 convertible note payable.
Company Officers & Contacts
Steven B. Rash
CEO
Steven B. Rash is a medical industry veteran with a lengthy list of career accomplishments and experiences. He has negotiated medical device licensing agreements and health care partner strategic alliances that combined have generated over $650 million in new revenues. Mr. Rash has also managed numerous drug trials and secured multiple FDA approvals. He has signed over 400 managed care contracts and made more than 200 Boardroom presentations at Fortune 500 companies. Mr. Rash has a BS in Business Administration from the University of Delaware and an MBA from Southern Illinois University. Mr. Rash is also a Veteran of the United States Army.
Barry A Ginsberg, O.D.
Consultant
Dr. Barry A. Ginsberg is an accomplished professional who advises executives across industries, bringing expertise in strategy and performance in the pharmaceuticals and medical-products sector. He also consults with healthcare companies to develop global strategies and operating models and is an experienced leader with a demonstrated history of success working as an entrepreneur in the health and wellness industry. He is skilled in comprehensive eye care which includes the diagnosis, treatment, management and prevention of diseases of the eye and visual system. Dr. Ginsberg has also participated in new Ophthalmic Drug and Procedure development trials utilizing his vast patient database. Combined with an expansive network of contacts and an exclusive key opinion leader database throughout North America, Europe, Middle East, Asia, and South America, he brings consummate value to the team.